5 research outputs found

    The ASCEND-NHQ trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis-dependent chronic kidney disease

    Get PDF
    The ASCEND-NHQ trial evaluated the effects of daprodustat on hemoglobin and the Medical Outcomes Study 36-item Short Form Survey (SF-36) Vitality score (fatigue) in a multicenter, randomized, double-blind, placebo-controlled trial. Adults with chronic kidney disease (CKD) Stages 3-5, hemoglobin 8.5-10.0 g/dl, transferrin saturation 15% or more, and ferritin 50 ng/ml or more without recent erythropoiesis-stimulating agent use were randomized (1:1) to oral daprodustat or placebo to achieve and maintain target hemoglobin of 11-12 g/dl over 28 weeks. The primary endpoint was the mean change in hemoglobin between baseline and the evaluation period (Weeks 24-28). Principal secondary endpoints were proportion of participants with a 1 g/dl or more increase in hemoglobin and mean change in the vitality score between baseline and Week 28. Outcome superiority was tested (one-sided alpha level of 0.025) among 614 randomized participants. The adjusted mean change in hemoglobin from baseline to the evaluation period was greater with daprodustat (1.58 vs 0.19 g/dl). The adjusted mean treatment difference (AMD) was significant at 1.40 g/dl (95% confidence interval 1.23, 1.56). A greater proportion of participants receiving daprodustat showed a significant 1 g/dl or more increase in hemoglobin from baseline (77% vs 18%). The mean SF-36 Vitality score increased by 7.3 and 1.9 points with daprodustat and placebo, respectively; a significant 5.4 point Week 28 ADM increase. Adverse event rates were similar (69% vs 71%); relative risk 0.98, (95% confidence interval 0.88, 1.09). Thus, in participants with CKD Stages 3-5, daprodustat resulted in a significant increase in hemoglobin and improvement in fatigue without an increase in the overall frequency of adverse events

    Comparison of landfarming amendments to improve bioremediation of petroleum hydrocarbons in Niger Delta soils

    No full text
    Large scale landfarming experiments, using an extensive range of treatments, were conducted in the Niger-Delta, Nigeria to study the degradation of oil in contaminated soils. In this work the effect of nutrient addition, biosurfactant, Eisenia fetida (earthworm) enzyme extract, bulking and sorption agents and soil neutralization were tested. It was found that these treatments were successful in removing up to 53% of the total petroleum hydrocarbon in the soil within 16 weeks. A comparison between treatments demonstrated that most were no more effective than agricultural fertilizer addition alone. One strategy that did show better performance was a combination of nutrients, biochar and biosurfactant, which was found to remove 23% more Total Petroleum Hydrocarbons (TPH) than fertilizer alone. However, when performance normalized costs were considered, this treatment became less attractive as a remedial option. Based on this same analysis it was concluded that fertilizer only was the most cost effective treatment. As a consequence, it is recommended that fertilizer is used to enhance the landfarming of hydrocarbon contaminated soils in the Niger Delta. The attenuation rates of both bulk TPH and Total Petroleum Hydrocarbon Criteria Working Group (TPHCWG) fractions are also provided. These values represent one of the first large scale and scientifically tested datasets for treatment of contaminated soil in the Niger Delta region. An inverse correlation between attenuation rates and hydrocarbon molecular weight was observed with heavy fractions showing much slower degradation rates than lighter fractions. Despite this difference, the bioremediation process resulted in significant removal of all TPH compounds independent of carbon number
    corecore